Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 7829558 Fused ring heterocycle kinase modulators

Patent 7829558 was granted and assigned to SGX Pharmaceuticals on November, 2010 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
‌
SGX Pharmaceuticals
Date Filed
September 22, 2008
Date of Patent
November 9, 2010
Patent Application Number
12235426
Patent Citations Received
‌
US Patent 11667632 2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof
0
‌
US Patent 11697649 Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof
0
‌
US Patent 11684615 Methods of using indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors
0
‌
US Patent 12012401 Process for preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
0
‌
US Patent 11780823 Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
7829558
Patent Primary Examiner
‌
D. Margaret Seaman

Find more entities like US Patent 7829558 Fused ring heterocycle kinase modulators

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.